Efficacy Study of Adalimumab to Treat Interstitial Cystitis
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate an investigational treatment for interstitial
cystitis. Interstitial cystitis is a chronic bladder disease that includes the following
symptoms: Urinary frequency during the day,urinary frequency at night, urinary urgency and
bladder discomfort relieved by voiding.
Presently, there is no cure for interstitial cystitis. The response to current treatments is
poor. Patients with interstitial cystitis have a poorer quality of life. The cause of
interstitial cystitis is unknown. This study is evaluating the drug Humira® (adalimumab) for
improving the symptoms of patients with interstitial cystitis. Humira® is an injectable
anti-inflammatory medication that has been available for use since December 31, 2002. Humira®
has been FDA approved for the treatment of rheumatoid arthritis, psoriasis, ankylosing
spondylitis, and Crohn's disease. These diseases have similar characteristics to interstitial
cystitis. This study will evaluate an investigational use of Humira® for the treatment of
interstitial cystitis.